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ABSTRACT 
The first clinical results from the EFFORTLESS S-ICD Registry on the entirely subcutaneous 
implantable defibrillator (S-ICD) system are promising, but the impact of the S-ICD system on 
patients’ quality of life (QoL) is not known. We evaluated the QoL of patients with an S-ICD 
against an unrelated cohort with a transvenous (TV)-ICD system during 6 months of follow-
up. Consecutively implanted patients with an S-ICD system were matched with patients with 
a TV-ICD system on a priori selected variables including baseline QoL. QoL was measured 
with the Short-Form Health Survey (SF-12) at baseline, 3- and 6 months post implant and 
compared using multivariable modelling with repeated measures. Patients with an S-ICD 
(n=167) versus a TV-ICD system (n=167) did not differ significantly on physical (p=0.8157) 
and mental QoL scores (p=0.9080) across baseline, 3- and 6 months post implantation in 
adjusted analyses. The evolution in physical (p=0.0503) and mental QoL scores (p=0.3772) 
during follow-up was similar for both cohorts, as indicated by the non-significant interaction 
effect for ICD system by time. Both patients with an S-ICD system and a TV-ICD system 
experienced significant improvements in physical and mental QoL between time of implant 
and 3 months (both ps<0.0001) and between time of implant and 6 months (both ps<0.0001) 
but not between 3 and 6 months (both ps>0.05). In conclusion, these first results show that 
the QoL of patients with an S-ICD versus TV-ICD system is similar, and that patients with 
either system experience improvements in QoL on the short-term.  
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INTRODUCTION  
The clinical efficacy of implantable cardioverter defibrillator (ICD) therapy is well established 
1,2, but due to risk of lead complications associated with the transvenous ICD (TV-ICD) 
system - referred to as the Achilles’ heel - the entirely subcutaneous ICD system (S-ICDTM 
system) was developed as an alternative3. The international Evaluation oF FactORs 
ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD (EFFORTLESS S-ICD) 
Registry was initiated in 2011 to evaluate the S-ICD system with respect to its clinical and 
system performance and its impact on patients in the ‘real world’ 4. The first clinical results 
based on data from 29 clinical sites across Europe and New Zealand demonstrate 
comparable performance of the S-ICD system with the TV-ICD system with respect to clinical 
conversion efficacy of discrete episodes of spontaneous ventricular tachycardia (VT) and 
ventricular fibrillation (VF) and inappropriate shock rates 5. The S-ICD system is now 
recommended in the 2015 European Society of Cardiology guidelines with a Class IIa 
indication in patients who are not dependent on pacing therapy for bradycardia, anti-
tachycardia or resynchronization pacing 6. In the current study, we compared (i) the QoL of 
patients with an entirely S-ICD system to an unrelated cohort of patients with a TV-ICD 
system, and (ii) the influence of the type of ICD system relative to symptomatic heart failure, 
personality, and shocks on QoL during 6 months’ follow-up, using data from the 
EFFORLESS Registry. 
 
METHODS 
The EFFORTLESS S-ICD Registry is an international, observational, prospective, non-
randomized, standard of care evaluation that includes both retrospective and prospective 
patients. However, the QoL substudy was designed to include only prospective and first-time 
implant patients that were recruited from 29 sites in the Czech Republic, Denmark, Germany, 
Italy, the Netherlands, New Zealand, Portugal, and the United Kingdom between the period 
of March 2011 to July 2014. Patients were eligible for inclusion if they were implanted with a 
first generation S-ICD system per local clinical guidelines due to a primary or secondary 
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prevention indication, and were willing to participate and provide written informed consent. 
Patients were excluded, if they participated in another study that was considered to interfere 
with interpretation of the results from the EFFORTLESS S-ICD Registry, had previously been 
implanted with an ICD, experienced incessant ventricular tachycardia and/or spontaneous, 
frequently recurring VT that could reliably be terminated with anti-tachycardia pacing, and if 
they had a bradycardia indication or cardiac resynchronization therapy (CRT). 
The QoL substudy of the EFFORTLESS S-ICD Registry was designed to use the 
MIDAS (Mood and personality as precipitants of arrhythmia in patients with an Implantable 
cardioverter Defibrillator: A prospective Study) cohort as a unrelated comparison group 4. 
MIDAS is a prospective observational study prior to the S-ICD era that recruited 
consecutively implanted patients with a first-time TV-ICD system between August 2003 and 
February 2010 at the Erasmus Medical Center, Rotterdam, the Netherlands 7,8.  
At each participating center, a member of staff approached patients for study 
participation at the time when patients were scheduled for the S-ICD implantation. All 
patients received oral and written information about the study. If willing to participate, they 
provided written informed consent. Patients would receive a reminder questionnaire if they 
did not return the first questionnaire. Similarly to the procedure in EFFORTLESS, patients 
from the MIDAS cohort were approached by a cardiologist or nurse about study participation. 
All patients received oral and written information about the study, and signed an informed 
consent form if they were willing to participate. 
The protocol for the EFFORTLESS S-ICD Registry was approved by the relevant 
medical ethics committees in each participating country. The Registry was conducted 
according to the Helsinki Declaration and ISO 14155:2009, and registered on 
http://www.ClinicalTrials.gov (NCT01085435). The protocol for the MIDAS cohort was 
approved by the medical ethics committee of the Erasmus Medical Center, Rotterdam, the 
Netherlands (MEC # 231.491/2003/148 - September 9, 2003). 
Information on clinical and demographic variables captured from the patients’ medical 
records was entered into an online case record form. As information on particular 
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demographic variables, such as education, marital status, participation in cardiac 
rehabilitation, and treatment for psychological problems are not entered standardly in 
patients’ medical records, these were included as purpose-designed questions in the 
questionnaire package containing the standardized and validated measures.  
QoL was assessed with the standardized and validated 12-Item Short-Form Health 
Survey (SF-12) at baseline, 3- and 6-months post implant9. The 12 items contribute to a 
Physical Component Summary (PCS) and a Mental Component Summary (MCS) score, with 
a range between 0-100 (0 = poorest possible QoL; 100 = best possible QoL) 9. Both PCS 
and MCS combine the 12 items in such a way that they compare to a national norm with a 
mean score of 50.0 and a standard deviation of 10.0. 
To control for the potentially confounding influence of personality on QoL, patients 
completed the Type D Scale (DS14) at baseline. The DS14 is a 14-item measure tapping 
into negative affectivity (e.g. ‘I often feel unhappy’) and social inhibition (e.g. ‘I am a closed 
kind of person’) 10. Items are rated on a 5-point Likert scale from 0-4 (score range for both 
subscales is 28), with a score of ≥10 on both traits indicating a Type D personality 10,11. The 
DS14 is a valid and internally consistent measure (Cronbach’s alpha: 0.80 for negative 
affectivity and 0.86 for social inhibition) 10. Type D personality is a vulnerability factor for 
poorer QoL, life-threatening arrhythmias and premature mortality in patients with an ICD 12-14.  
Prior to propensity score matching, patients from the MIDAS cohort who had an 
indication for bradycardia or CRT, or with a secondary prevention indication due to 
monomorphic VTs were excluded from analyses, as these patients are not eligible for an S-
ICD system. EFFORTLESS and MIDAS patients were matched 1:1 using propensity score 
matching on the following a priori selected variables: Gender, age, indication for ICD (primary 
versus secondary), ischemic versus non-ischemic etiology and baseline physical QoL and 
mental QoL. Propensity score matching was performed using the greedy matching algorithm 
with the recommended caliper width by Austin 15. Multivariable modelling with repeated 
measures was used to analyze physical QoL and mental QoL across the visits, baseline, 3- 
and 6 months post implantation. The time by ICD system (S-ICD versus TV) interaction was 
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also considered in the multivariable modeling, if statistically significant at the 0.05 level. In a 
first model, a priori based on the literature, we choose to adjust for the following factors that 
might serve as potential confounders on QoL in multivariable analysis: Low education, NYHA 
functional class III-IV, amiodarone, cardiac rehabilitation attendance, treatment for 
psychological problems, Type D personality, and shocks during the 6 months’ follow-up 
period. In a second model, we adjusted additionally for all baseline factors that were 
significantly different between the EFFORTLESS and MIDAS cohorts despite matching. Data 
were analyzed using SAS version 9.2.  
 
RESULTS 
Of the 419 EFFORTLESS patients prospectively enrolled, 95% (397/419) consented to 
participate. Of these patients, 17% (68 of 397) were excluded due to previous implantation 
with a TV-ICD system or pacemaker, while 20% (80 of 397) patients were excluded due to 
insufficient QoL data. After matching EFFORTLESS patients with patients from the MIDAS 
cohort using propensity score matching, data from 167 patients with an S-ICD and 167 
patients with a TV-ICD system were used for analyses. A flowchart of the patient selection is 
shown in Figure 1. 
Baseline characteristics of the 2 cohorts are presented in Table 1. Despite propensity 
score matching on a priori selected variables, the EFFORTLESS and MIDAS cohorts differed 
on some baseline characteristics. EFFORTLESS patients were less likely to have VF as 
index arrhythmia, to be prescribed statins and diuretics, but more likely to have a lower QRS 
duration as compared to the MIDAS patients. EFFORTLESS patients were more likely to 
have VT as index arrhythmia, and to have diabetes and heart failure than MIDAS patients. 
There were no systematic differences on any of the other characteristics, including 
personality and baseline QoL (the latter was one of the matching criteria). 
During the 6 months’ follow-up period, in the matched cohort of equal size (n=167) 
and equal follow-up (6 months), 19 episodes were treated with a shock in the Effortless 
cohort as compared to 29 in the MIDAS cohort. 
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Multivariable modelling examining the effect of ICD system, time, and ICD system by 
time interaction showed that the interaction was neither statistically significant for physical 
QoL (p=0.0503) nor mental QoL (p=0.3772), indicating that the evolution in QoL scores 
during the 6-months of follow-up was similar in patients with either an S-ICD or a TV-ICD 
system.  
Therefore, analyses were run again including only the main effects for ICD system 
and time. These unadjusted analyses (without the interaction effect) showed no statistically 
significant main effects for ICD system (S-ICD versus TV) neither on physical (p=0.1707) nor 
on mental QoL (p=0.3364) across baseline, 3- and 6 months post implantation. When 
adjusting for a priori determined potential confounders (i.e., low education, NYHA functional 
class III-IV, amiodarone, cardiac rehabilitation attendance, treatment for psychological 
problems, Type D personality, and shocks during the 6 months follow-up period), the model 
estimate when comparing the 2 cohorts was statistically significant for physical QoL 
(p=0.0324) but not for mental QoL (p=0.2232) (Table 2 - Model 1). The mean score 
differences on physical and mental QoL between the 2 cohorts were largest at baseline with 
2.32 (on a scale from 0-100) with the MIDAS cohort experiencing a slightly better QoL. For 
mental QoL, the same pattern was seen, although the highest mean score difference 
between the 2 cohorts was at 6 months with a mean score difference of 1.26 (on a scale 
from 0-100). When adding also differences between the 2 cohorts on baseline characteristics 
to the variables entered in Model 1, the largest mean difference between the 2 cohorts was 
reduced to 0.29 for physical QoL and to 0.14 for mental QoL (Table 2 – Model 2). Neither 
the model estimate for differences in physical (p=0.8157) nor mental QoL (p=0.9080) 
between the 2 cohorts was statistically significant. Shocks during follow-up were neither 
associated with physical QoL (p=0.5648) nor mental QoL (p=0.5161) in Model 2, which was 
fully adjusted. 
The main effect for time was statistically significant, indicating that both cohorts 
improved in physical (p>0.0001) and mental QoL (p>0.0001) during the 6-months of follow-
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up. Test for differences between time intervals for physical QoL, including a priori specified 
factors and baseline differences between the 2 cohorts, showed that both patients with an S-
ICD system and a TV-ICD system experienced significant improvements in physical QoL 
between the time of implant and 3 months (p<0.0001) and between the time of implant and 6 
months (p<0.0001) but not between 3 and 6 months (p=0.8239). We found similar results for 
mental QoL, with both patients with an S-ICD system and a TV-ICD system experiencing 
significant improvements between the time of implant and 3 months (p<0.0001) and between 
the time of implant and 6 months (p<0.0001) but not between 3 and 6 months (p=0.3912). 
Absolute differences in the unadjusted physical and mental QoL scores at baseline, 
3- and 6 months, stratified by ICD system, symptomatic heart failure, personality, and shocks 
during 6 months of follow-up are shown in Figures 2a-b. When evaluating mean score 
differences in physical and mental QoL scores across baseline, 3- and 6 months follow-up 
between patients (i) with an S-ICD versus a TV-ICD system, (ii) NYHA class I-II versus III-IV, 
(iii) Type D versus a non-Type D personality, and (iv) shocks versus no shocks during follow-
up, there is the least differentiation between the 2 ICD systems both in physical (range: 0.10-
2.70) and mental QoL scores (range: 0.30-2.30) across the 3 time points (Figure 3). For 
physical QoL, the largest difference was seen between patients with NYHA class I-II versus 
III-IV, with a mean score difference range of 9.10-10.90, while for mental QoL the largest 
differentiation was between patients with a Type D versus non-Type D personality, with a 
mean score difference range of 8.9-9.7. This indicates that the type of ICD system has less 
of an impact on patients’ physical and mental QoL relative to symptomatic heart failure 
(NYHA class III-IV), personality, and shocks during follow-up. 
 
DISCUSSION 
In the current article, we present the first results of the multi-center, international 
EFFORTLESS QoL substudy comparing patients with an entirely S-ICD system to an 
unrelated control cohort of patients with a TV-ICD system. We found a statistically significant 
but minimal mean difference of 2.32 points in physical but not mental QoL between the 2 
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cohorts, with this difference disappearing after adjustment for confounders. Thus, overall, the 
physical and mental QoL of patients with an S-ICD and a TV-ICD system are similar across 
baseline, 3- and 6 months post implantation, and both cohorts improved in physical and 
mental QoL over time, with the evolution of changes in QoL scores over time being similar.  
These findings emphasize that the type of device, and in this case also the difference 
in size and weight between the pulse generator of the S-ICD versus the TV-ICD system - the 
S-ICD is considerably larger and weighs almost the double (145 g) of the TV-ICD system 16 -
has negligible impact on patients’ well-being and QoL at least up to 6 months of follow-up. In 
part, the concern with respect to size may be more on the physician side, as they know the 
difference in size between a TV-ICD versus S-ICD, while patients with an S-ICD in most 
cases are unlikely to be able to make this comparison. There is also no indication that the 
mean QoL scores found both in the S-ICD and MIDAS cohorts differ systematically from 
those reported in other TV cohorts 17,18. Similarly, as in previous studies of patients with a 
TV-ICD system (excluding previously published findings from the MIDAS cohort), we found 
that other factors, in particular symptomatic heart failure and personality, may be more 
important determinants of QoL than the type of device itself and having a device 19-22.  
The results of this study should be interpreted with the following limitations in mind. 
The MIDAS patients used as controls cohort for the EFFORTLESS S-ICD patients was 
obtained from a single center and recruited over a period of 7 years as compared to 3 years 
for EFFORTLESS patients. Nevertheless, the mean QoL scores of the MIDAS patients did 
not differ systematically from other TV-ICD cohorts from Denmark and China 17,18. Given that 
the eligibility criteria for the S-ICD system differ from those for a TV-ICD system, we had to 
exclude some of the MIDAS patients from the comparison cohort prior to matching, reducing 
the number of patients available. In addition, a priori we had decided to match the 2 cohorts 
on pre-selected baseline characteristics. Although the matching eradicated some of the 
differences between the 2 cohorts, they still differed on some baseline characteristics, in 
particular on medication prescription. However, we adjusted statistically for these differences 
in statistical analyses. As there is no disease-specific measure to tap into the QoL of patients 
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with an ICD, we used the SF-12, a generic and international standard of QoL that has been 
used either in its short- (SF-12) or long form (SF-36) in the seminal primary and secondary 
prevention trials, such as DEFINITE 23 and SCD-HEFT 24. Although this generic measure 
may be less sensitive to demonstrate changes over time and differences between groups, 
DEFINITE demonstrated almost equivalent changes in scores on the SF-12 and the 
Minnesota Living with Heart Failure questionnaire.  
This study also has several strengths. First, it evaluates the patient perspective by 
asking patients to evaluate the impact of a new device on their well-being and QoL. Such a 
patient-centered approach has not only been advocated by the Institute of Medicine in the 
US 25, but also the American Heart Association 26 and the European Society of Cardiology 27. 
Second, EFFORTLESS patients were included from 29 clinical sites not only across Europe 
but also New Zealand. Third, both the EFFORTLESS and MIDAS cohorts were well 
described not only in terms of their demographic and clinical characteristics but also their 
psychological profile. Fourth, final statistical models were fully adjusted including adjustment 
for differences in baseline characteristics that were not resolved via matching and shocks 
during follow-up as a time-varying variable. 
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Table 1. Baseline characteristics for the EFFORTLESS (S-ICD) and MIDAS (TV-ICD) cohorts 
 
Characteristics EFFORTLESS MIDAS p 
     (S-ICD system)  (TV-ICD system) 
 (n = 167) (n = 167) 
 
Men 122 (73%) 120 (72%) 0.8065  
Age, mean ±SD (years) 54 ± 16 55 ± 13 0.8831  
Low education (<13 years) 73 (45%) 90 (55%) 0.0597 
Primary prevention indication 123 (74%) 115 (69%) 0.3334  
Ventricular fibrillation  
as index arrhythmia 32 (20%) 50 (30%) 0.0480  
Ventricular tachycardia 
as index arrhythmia 8 (5%)  2 (1%) 0.0426 
Atrial fibrillation 36 (22%)  30 (18%) 0.4097  
Diabetes mellitus 31 (19%)  16 (10%)  0.0183  
Heart failure 69 (41%) 28 (17%) <0.0001  
NYHA III-IV 20 (12%) 24 (15%) 0.5313  
Renal failure (60 ml/kg/1.73m2)  13 (8%) 23 (14%) 0.0841  
Transient ischemic attack  
or stroke 13 (8%) 8 (5%) 0.2781  
Dilated cardiomyopathy 25 (15%) 39 (23%) 0.0516  
Ischemic cardiomyopathy 12 (7%) 12 (7%) 1.0000  
Hypertrophic cardiomyopathy 22 (13%)  18 (11%) 0.5002  
QRS duration 105 ± 21 112 ± 27 0.0071  
Previous myocardial infarction 66 (40%) 68 (40%) 0.8223  
Previous percutaneous  
coronary intervention 32 (19%)  42 (25%)  0.1877  
Previous coronary bypass 17 (10%)  17 (10%)  1.0000 
Amiodarone 15 (9%)  12 (7%)  0.5470  
Beta-blockers 125 (75%) 133 (80%) 0.2964  
Digoxin 10 (6%) 17 (10%) 0.1600  
Statins 50 (30%) 75 (45%) 0.0047  
Angiotension converting 
enzyme inhibitors 92 (55%) 106 (64%) 0.1190  
Diuretics 80 (48%) 57 (34%) 0.0105 
Cardiac rehabilitation 7 (4%) 11 (7%) 0.3593  
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Treatment for psychological  
problems † 9 (5%) 14 (8%)  0.2798 
Type D personality 44 (27%) 35 (21%)  0.2461 
Baseline physical quality of 
life (PCS), mean ±SD 41 ± 12 41 ± 11  0.9787  
Baseline mental quality of 
life (MCS), mean ±SD 42 ± 12 43 ± 12 0.8697  
 
 
† Currently seeing a social worker, psychologist or psychiatrist for psychological problems 
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Table 2. Physical and mental quality of life of patients with an S-ICD system versus a TV-ICD 
system during the course of 6-months follow-up post implant  
 
  EFFORTLESS        MIDAS 
 (S-ICD system)    (TV-ICD system) 
   
 Mean [95% CI]  Mean [95% CI]       p-value 
 
Model 1 a 
 
Physical QoL (PCS)   
Baseline 39.35 [37.75-40.95] 41.61 [40.02-43.19] 0.032   
3 months 42.42 [40.87-43.98] 44.68 [43.15-46.21]  
6 months 42.33 [40.72-43.93] 44.58 [43.00-46.17]  
   
Mental QoL (MCS)   
Baseline 41.60 [40.00-43.19] 42.84 [41.27-44.42] 0.2232 
3 months 45.12 [43.53-46.71] 46.37 [44.80-47.93]  
6 months 44.52 [42.85-46.20] 45.78 [44.12-47.41]  
______________________________________________________ 
 
Model 2 b 
 
Physical QoL (PCS)    
Baseline 40.48 [38.69-42.27] 40.77 [39.12-42.42]  0.8157 
3 months 43.56 [41.79-45.34] 43.85 [42.22-45.48]  
6 months 43.45 [41.63-45.26] 43.74 [42.06-45.41]  
   
Mental QoL (MSC)   
Baseline 42.39 [40.60-44.19] 42.25 [40.59-43.92] 0.9080 
3 months 45.86 [44.04-47.68] 45.72 [44.04-47.40]  
6 months 45.19 [43.29-47.09] 45.05 [43.28-46.81]  
 
 
* adjusted for a priori selected covariates  
† adjusted for a priori selected covariates and baseline differences between the two cohorts   
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Figure 1. Flowchart of patient selection 
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Figure 2. Comparison of mean physical and mental QoL scores at baseline, 3- and 6-months 
follow-up, stratified by ICD system, symptomatic heart failure, personality, and shocks during 
follow-up (unadjusted analysis)* 
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Figure 3. Mean physical and mental QoL score differences at baseline, 3- and 6 months 
stratified by ICD system, symptomatic heart failure, personality, and shocks during follow-up 
(unadjusted analysis)* 
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